http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#Head http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#assertion http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#provenance http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#pubinfo http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#assertion http://purl.obolibrary.org/obo/DOID_4074 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_4074 http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00441 http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#association http://www.w3.org/2000/01/rdf-schema#label gemcitabine for injection is a nucleoside metabolic inhibitor indicated in combination with carboplatin for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum based therapy 1 1 in combination with paclitaxel for first line treatment of metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy unless anthracyclines were clinically contraindicated 1 2 in combination with cisplatin for the treatment of non small cell lung cancer 1 3 as a single agent for the treatment of pancreatic cancer 1 4 gemcitabine for injection in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum based therapy gemcitabine for injection in combination with paclitaxel is indicated for the first line treatment of patients with metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy unless anthracyclines were clinically contraindicated gemcitabine for injection is indicated in combination with cisplatin for the first line treatment of patients with inoperable locally advanced stage iiia or iiib or metastatic stage iv non small cell lung cancer gemcitabine for injection is indicated as first line treatment for patients with locally advanced nonresectable stage ii or stage iii or metastatic stage iv adenocarcinoma of the pancreas gemcitabine for injection is indicated for patients previously treated with 5 fu http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00441 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#provenance http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#pubinfo http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#sig http://purl.org/nanopub/x/hasSignature Ph39F+yDFxevQlCSn/wVWKZBMavNM5dnIXW46fmkxgoJqtTkfsgaQ1eSFt58fQx65R+0kvuUCOceDvmzRMytyrSEaoQptBi6emyMkJaKmZv2/xP3FlZLF/7iTCjb10dcxu6gT/Fe2BSkHNxHp/xvFTV4VFsknQEYor+EGmrC1OQ= http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI http://purl.org/dc/terms/created 2021-06-15T18:39:39.624+02:00 http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAAG7Y8axBangTIAQpju8UNY52H_c3nn4abGz9_HArVXI https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs